Skip to main content
Donald Kufe, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

DonaldWilliamKufeMD

Oncology Boston, MA

Professor of Medicine, Dana-Farber Cancer Institute

Are you Dr. Kufe?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 60 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Donald Kufe, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Education & Training

  • George Washington University
    George Washington UniversityResidency, Internal Medicine, 1975 - 1977
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterInternship, Transitional Year, 1970 - 1971
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1970

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1977 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1982

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers
    Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 31st, 2023

Grant Support

  • Functional Role Of The MUC1-C Oncoprotein In Non-Small Cell Lung CancerNational Cancer Institute2012
  • Adoptive Immunotherapy For Multiple Myeloma Using Educated T CellsNational Cancer Institute2010–2012
  • Early Clinical Trials Of New Anti-Cancer Agents With Phase I EmphasisNational Cancer Institute2008–2012
  • P5 - Adoptive Immunotherapy For Renal Carcinoma Usng Dendritic Cell/Tumor FusionsNational Cancer Institute2010–2011
  • Oncogenic Signaling By DF3/MUC1 In Human Breast CancerNational Cancer Institute2002–2011
  • Differentiating Agents In Hematologic MalignanciesNational Cancer Institute1986–2011
  • Adoptive Immunotherapy For Renal Carcinoma Using Dendritic Cell/Tumor FusionsNational Cancer Institute2009
  • Novel Immunotherapeutic Approaches For Ovarian CancerNational Cancer Institute2004–2008
  • Regulation Of Oxidative Stress Response By C-ABL And ARGNational Cancer Institute2003–2007
  • Phase I Trials Of New Anti-Cancer AgentsNational Cancer Institute2003–2007
  • Molecular Mechanisms Of ARA-C Therapy In ManNational Cancer Institute1987–2005
  • Development Of Myeloma VaccinesNational Cancer Institute1998–2002
  • Molecular Regulation Of Signaling By Ionizing RadiationNational Cancer Institute1996–2002
  • Phase I Trials Of New Anticancer AgentsNational Cancer Institute1994–2002
  • Oncogenic Signaling By The MUC1 Breast Carcinoma AntigenNational Cancer Institute2000–2001
  • Phosphorylation Of RAD51National Center For Research Resources1998–2001
  • Core--Cancer PharmacologyNational Cancer Institute2000
  • DF3/MUC1 Vaccine And Stamp Therapy For Breast CancerNational Cancer Institute1997–1998
  • Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
  • Molecular Regulation Of C-Jun By Ionizing RadiationNational Cancer Institute1992–1994
  • Clonality In Acute Myeloid Leukemia And MyelodysplasiaNational Cancer Institute1991–1992
  • Immunodiagnostic Approaches To Human Breast CancerNational Cancer Institute1985–1990
  • Molecular Mechanisms Of ARA C Therapy In ManNational Cancer Institute1985–1986
  • Molecular Mechanisms Of 5-Fluorouracil ChemotherapyNational Cancer Institute1985–1986

Hospital Affiliations